Prio Wealth Limited Partnership Cuts Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Prio Wealth Limited Partnership lessened its position in Becton, Dickinson and Company (NYSE:BDX) by 1.7% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 132,678 shares of the medical instruments supplier’s stock after selling 2,356 shares during the quarter. Prio Wealth Limited Partnership’s holdings in Becton, Dickinson and Company were worth $31,989,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of BDX. Sound Income Strategies LLC raised its holdings in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the period. Opal Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at $45,000. Abound Wealth Management grew its stake in Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares in the last quarter. Chilton Capital Management LLC grew its stake in Becton, Dickinson and Company by 1,233.3% during the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 185 shares in the last quarter. Finally, Tributary Capital Management LLC acquired a new position in Becton, Dickinson and Company during the 1st quarter worth $49,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on BDX shares. Evercore ISI boosted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Raymond James lowered their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Stock Down 0.9 %

Shares of NYSE:BDX traded down $2.10 on Monday, hitting $241.65. 106,729 shares of the company’s stock were exchanged, compared to its average volume of 1,387,929. The firm’s 50-day moving average is $237.01 and its 200 day moving average is $235.18. The company has a market capitalization of $69.84 billion, a PE ratio of 53.69, a P/E/G ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $262.23. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.96 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were given a $0.95 dividend. The ex-dividend date was Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.57%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.